Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jul;39(7):1606–1608. doi: 10.1128/aac.39.7.1606

Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.

C J Carlyn 1, L J Doyle 1, C C Knapp 1, M D Ludwig 1, J A Washington 1
PMCID: PMC162791  PMID: 7492114

Abstract

Between 1 January 1992 and 31 December 1993, our laboratory, as part of the Gonococcal Isolate Surveillance Project, found that 39 of 673 isolates of Neisseria gonorrhoeae from one local sexually transmitted diseases clinic demonstrated decreased susceptibilities to both ciprofloxacin and ofloxacin. The MICs of BAY y 3118, DU-6859a, and clinafloxacin at which 90% of the gonococci with decreased susceptibility to ciprofloxacin and ofloxacin were inhibited were all 0.016 microgram/ml, which was eightfold higher than those for ciprofloxacin-susceptible gonococci. Our report substantiates prior observations that diminished susceptibility to one quinolone is often associated with diminished susceptibility to other quinolones.

Full Text

The Full Text of this article is available as a PDF (180.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bogaerts J., Tello W. M., Akingeneye J., Mukantabana V., Van Dyck E., Piot P. Effectiveness of norfloxacin and ofloxacin for treatment of gonorrhoea and decrease of in vitro susceptibility to quinolones over time in Rwanda. Genitourin Med. 1993 Jun;69(3):196–200. doi: 10.1136/sti.69.3.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bryan J. P., Hira S. K., Brady W., Luo N., Mwale C., Mpoko G., Krieg R., Siwiwaliondo E., Reichart C., Waters C. Oral ciprofloxacin versus ceftriaxone for the treatment of urethritis from resistant Neisseria gonorrhoeae in Zambia. Antimicrob Agents Chemother. 1990 May;34(5):819–822. doi: 10.1128/aac.34.5.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clendennen T. E., 3rd, Hames C. S., Kees E. S., Price F. C., Rueppel W. J., Andrada A. B., Espinosa G. E., Kabrerra G., Wignall F. S. In vitro antibiotic susceptibilities of Neisseria gonorrhoeae isolates in the Philippines. Antimicrob Agents Chemother. 1992 Feb;36(2):277–282. doi: 10.1128/aac.36.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Erwin M. E., Jones R. N. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium. J Clin Microbiol. 1992 May;30(5):1170–1173. doi: 10.1128/jcm.30.5.1170-1173.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fass R. J. In vitro activity of Bay y 3118, a new quinolone. Antimicrob Agents Chemother. 1993 Nov;37(11):2348–2357. doi: 10.1128/aac.37.11.2348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fuchs P. C., Barry A. L., Baker C., Murray P. R., Washington J. A., 2nd Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin. J Clin Microbiol. 1991 Oct;29(10):2111–2114. doi: 10.1128/jcm.29.10.2111-2114.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gorwitz R. J., Nakashima A. K., Moran J. S., Knapp J. S. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ. 1993 Aug 13;42(3):29–39. [PubMed] [Google Scholar]
  8. Gransden W. R., Warren C., Phillips I. 4-Quinolone-resistant Neisseria gonorrhoeae in the United Kingdom. J Med Microbiol. 1991 Jan;34(1):23–27. doi: 10.1099/00222615-34-1-23. [DOI] [PubMed] [Google Scholar]
  9. Hook E. W., 3rd, Jones R. B., Martin D. H., Bolan G. A., Mroczkowski T. F., Neumann T. M., Haag J. J., Echols R. Comparison of ciprofloxacin and ceftriaxone as single-dose therapy for uncomplicated gonorrhea in women. Antimicrob Agents Chemother. 1993 Aug;37(8):1670–1673. doi: 10.1128/aac.37.8.1670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jephcott A. E., Turner A. Ciprofloxacin resistance in gonococci. Lancet. 1990 Jan 20;335(8682):165–165. doi: 10.1016/0140-6736(90)90035-4. [DOI] [PubMed] [Google Scholar]
  11. Jones R. N., Barrett M. S., Biedenbach D. J. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae. Diagn Microbiol Infect Dis. 1994 Jun;19(2):93–99. doi: 10.1016/0732-8893(94)90119-8. [DOI] [PubMed] [Google Scholar]
  12. Otubu J. A., Imade G. E., Sagay A. S., Towobola O. A. Resistance of recent Neisseria gonorrhoeae isolates in Nigeria and outcome of single-dose treatment with ciprofloxacin. Infection. 1992 Nov-Dec;20(6):339–341. doi: 10.1007/BF01710680. [DOI] [PubMed] [Google Scholar]
  13. Tapsall J. W., Shultz T. R., Phillips E. A. Characteristics of Neisseria gonorrhoeae isolated in Australia showing decreased sensitivity to quinolone antibiotics. Pathology. 1992 Jan;24(1):27–31. doi: 10.3109/00313029209063616. [DOI] [PubMed] [Google Scholar]
  14. Yeung K. H., Dillon J. R. Norfloxacin resistant Neisseria gonorrhoeae in North America. Lancet. 1990 Sep 22;336(8717):759–759. doi: 10.1016/0140-6736(90)92261-f. [DOI] [PubMed] [Google Scholar]
  15. Zenilman J. M., Neumann T., Patton M., Reichart C. Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1993 Oct;37(10):2244–2246. doi: 10.1128/aac.37.10.2244. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES